New combo aims to fight lung cancer that outsmarted earlier drugs
NCT ID NCT07001995
First seen Mar 26, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This study tests a combination of limertinib (a targeted pill) plus two chemotherapy drugs (carboplatin and etoposide) in 30 adults with a specific type of lung cancer. These patients had non-small cell lung cancer with an EGFR mutation, but after initial targeted therapy stopped working, their cancer transformed into a more aggressive small-cell type. The goal is to see if this new combo can slow or stop the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yongchang Zhang
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.